Bispecific Antibodies in Multiple Myeloma: Present and Future von Lancman, Guido, Sastow, Dahniel L, Cho, Hearn J, Jagannath, Sundar, Madduri, Deepu, Parekh, Samir S, Richard, Shambavi, Richter, Joshua, Sanchez, Larysa, Chari, Ajai

Volltext

IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies von Lancman, Guido, Parsa, Kian, Kotlarz, Krzysztof, Avery, Lisa, Lurie, Alaina, Lieberman-Cribbin, Alex, Cho, Hearn Jay, Parekh, Samir S, Richard, Shambavi, Richter, Joshua, Rodriguez, Cesar, Rossi, Adriana, Sanchez, Larysa J, Thibaud, Santiago, Jagannath, Sundar, Chari, Ajai

Volltext

Phase 1 study of elotuzumab in combination with autologous stem cell transplantation and lenalidomide maintenance for multiple myeloma von Osman, Keren, Cho, Hearn J., Chari, Ajai, Parekh, Samir S.

Volltext

ISS stage and network risk score to predict benefits of multiple myeloma treatment options von Liu, Yu, Wang, Li, Yu, Haocheng, Parekh, Samir S., Schadt, Eric, Zhu, Jun

Volltext

Early detection of CRS after CAR-T therapy using wearable monitoring devices: Preliminary results in relapsed/refractory multiple myeloma (RRMM) von Rajeeve, Sridevi, Wilkes, Matt, Zahradka, Nicole, Serebyrakova, Kseniya, Kappes, Katerina, Jackson, Hayley, Buchenholz, Nicole, Agte, Sarita, Thibaud, Santiago, Sanchez, Larysa Jessica, Richard, Shambavi, Richter, Joshua Ryan, Rodriguez, Cesar, Cho, Hearn J., Chari, Ajai, Jagannath, Sundar, Rossi, Adriana, Parekh, Samir S.

Volltext

A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with r... von Berdeja, Jesus G., Martin, Thomas G., Rossi, Adriana, Essell, James H., Siegel, David Samuel DiCapua, Mailankody, Sham, Saini, Neeraj, Holmes, Houston, Dhakal, Binod, Gasparetto, Cristina J., Parekh, Samir S., Portella, Socorro, Ledergor, Guy, Hammad, Ashley, Davi, Franco, Skoble, Justin, Garner, Elizabeth, Kanner, Steven Brian, Rizvi, Syed, Jagannath, Sundar

Volltext

ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect... von Smith, Mitchell Reed, Jegede, Opeyemi, Martin, Peter, Till, Brian G., Parekh, Samir S., Yang, David T, Kostakoglu, Lale, Casulo, Carla, Bartlett, Nancy L., Caimi, Paolo Fabrizio, Al Baghdadi, Tareq, Maddocks, Kami J., Romer, Mark D., Inwards, David James, Lerner, Rachel E., Wagner, Lynne I., Little, Richard F., Friedberg, Jonathan W., Leonard, John Paul, Kahl, Brad S.

Volltext

Incidence, mitigation, and management of neurologic adverse events in patients with multiple myeloma (MM) treated with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-2 von Einsele, Hermann, Parekh, Samir S., Madduri, Deepu, Santomasso, Bianca, Gállego Pérez De Larraya, Jaime, van de Donk, Niels W.C.J., Arnulf, Bertrand, Mateos, Maria-Victoria, De Braganca, Kevin C., Varsos, Helen, Carrasco-Alfonso, Marlene, Akram, Muhammad, Lendvai, Nikoletta, Jackson, Carolyn Chang, Olyslager, Yunsi, Zudaire, Enrique, Li, Claire, Geng, Dong, Jakubowiak, Andrzej J., Cohen, Adam D.

Volltext

Paradigms and Controversies in the Treatment of HIV-Related Burkitt Lymphoma von Petrich, Adam M., Parekh, Samir, Sparano, Joseph A.

Volltext

Phase I-b study of isatuximab + carfilzomib in relapsed and refractory multiple myeloma (RRMM) von Chari, Ajai, Richter, Joshua Ryan, Shah, Nina, Wong, Sandy Wai Kuan, Jagannath, Sundar, Cho, Hearn J., Biran, Noa, Wolf, Jeffrey, Parekh, Samir S., Munster, Pamela N., Madduri, Deepu, Campana, Frank, Martin, Thomas G.

Volltext

A phase I study of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid tumors and hematological malignancies von Blazquez, Ana, Rubinsteyn, Alex, Kodysh, Julia, Finnigan, John Patrick, Marron, Thomas Urban, Meseck, Marcia, O'Donnell, Timothy, Hammerbacher, Jeffrey, Donovan, Michael J., Mahajan, Milind, Miles, Brett A., Irie, Hanna, Tiersten, Amy, Tewari, Ashutosh, Parekh, Samir S., Nair, Sujit, Galsky, Matt D., Schadt, Eric E., Friedlander, Philip Adam, Bhardwaj, Nina

Volltext

Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas von Parekh, Samir, Privé, Gilbert, Melnick, Ari

Volltext

A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers von Kyi, Chrisann, Sabado, Rachel Lubong, Blazquez, Ana, Posner, Marshall R., Genden, Eric Michael, Miles, Brett A., Khorasani, Hooman, Dottino, Peter Remsen, Irie, Hanna, Port, Elisa R., Wolf, Andrea S, Cho, Hearn J., Parekh, Samir S., Mandeli, John, Galsky, Matthew, Oh, William K., Gnjatic, Sacha, Schadt, Eric E., Friedlander, Philip Adam, Bhardwaj, Nina

Volltext

A phase II study of panobinostat with lenalidomide and weekly dexamethasone in myeloma von Chari, Ajai, Cho, Hearn J., Parekh, Samir S., Dhadwal, Amishi, Garcia, Katarzyna, Morgan, Gillian, Belostotsky, Natalie, Carter, Crystle, Catamero, Donna, Escalon, Juliet, Verina, Daniel, Yum, Moon-Hee, La, Lisa, Chan, Elaine, Gullie, Jude, Jagannath, Sundar

Volltext

Effect of phosphotidylinositol 3-kinase-delta inhibitor idelalisib (GS-1101) on signaling in primary non-Hodgkin lymphoma cells: Correlative studies from NCT01306643 von Arita, Adriana, Hanlon, Katherine, Chkourko, Halina, Lannutti, Brian Joseph, Johnson, David Michael, Gabrilove, Janice Lynn, Scigliano, Eileen, Parekh, Samir S., Brody, Joshua

Volltext

Abstract A005: A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers von Blazquez, Ana B., Rubinsteyn, Alex, Kodysh, Julia, Finnigan, John P., Marron, Thomas, Sabado, Rachel L., Meseck, Marcia, O'Donnell, Timothy J., Hammerbacher, Jeffrey, Donovan, Michael, Holt, John, Mahajan, Milind, Mandeli, John, Misiukiewicz, Krysztof, Genden, Eric M., Milles, Brett A., Khorasani, Hooman, Dottino, Peter R., Irie, Hanna, Tiersten, Amy B., Port, Elisa R., Wolf, Andrea S., Cho, Hern J., Tewari, Ashutosh, Parekh, Samir S., Nair, Sujit, Galsky, Matthew D., Oh, William K., Gnjatic, Sacha, Schadt, Eric E., Friedlander, Phillip A., Bhardwaj, Nina

Volltext

Targeting HSF1: A Prime Integrator of Proteotoxic Stress Response in Myeloma von Parekh, Samir

Volltext

Discovery of a first-in-class EZH2 selective degrader von Ma, Anqi, Stratikopoulos, Elias, Park, Kwang-Su, Wei, Jieli, Martin, Tiphaine C., Yang, Xiaobao, Schwarz, Megan, Leshchenko, Violetta, Rialdi, Alexander, Dale, Brandon, Lagana, Alessandro, Guccione, Ernesto, Parekh, Samir, Parsons, Ramon, Jin, Jian

Volltext

Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy von Van Oekelen, Oliver, Aleman, Adolfo, Upadhyaya, Bhaskar, Schnakenberg, Sandra, Madduri, Deepu, Gavane, Somali, Teruya-Feldstein, Julie, Crary, John F., Fowkes, Mary E., Stacy, Charles B., Kim-Schulze, Seunghee, Rahman, Adeeb, Laganà, Alessandro, Brody, Joshua D., Merad, Miriam, Jagannath, Sundar, Parekh, Samir

Volltext

Abnormal Lipid and Glucose Metabolism in Obesity: Implications for Nonalcoholic Fatty Liver Disease von Parekh, Samir, Anania, Frank A

Volltext